Skip to main content

Protagen, Scienion Ink Partnership

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protagen today announced that Scienion will produce protein microarray batches of more than 1,000 arrays for Protagen for the clinical validation of biomarker panels.

In addition, under a strategic partnership, the two Dortmund, Germany-based firms will jointly evaluate new platforms for multiplexed analytics and co-develop new approaches up to proof-of-concept levels.

Financial and other terms of the deal were not disclosed.

Peter Schulz-Knappe, CSO of Protagen, said in a statement that Scienion's sciFlexarrayer nanodispensing technology allows for the manufacture of protein microarray batches, each with more than 3,500 single proteins with "the highest quality and reproducibility."

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.